RIPE-KG · Version 1.1.0 · Resource
ripekg:publication-details/RIPEA3A616563C128D80E
https://w3id.org/ripe/ripe-kg/publication-details/RIPEA3A616563C128D80E
| Subject | Predicate | Object |
|---|---|---|
ripekg:evaluation/RIPEA3A616563C128D80E |
prov:used |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:eIssn |
1099-1573 |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:endingPage |
2125 |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:issn |
0951-418X |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:publicationDate |
2019-07 |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:publicationName |
Phytotherapy Research |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prism:startingPage |
2118 |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
dcterms:publisher |
ripekg:publisher/RIPEP932ECA8E36309A4DWiley |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
dcterms:title |
Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
http://purl.org/spar/fabio/BibliographicMetadata |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
rdfs:Resource |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
owl:Thing |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
ripe:PublicationDetailsPublication details |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
rdf:type |
tido:Evidence |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA3A616563C128D80E |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
ripe:concerns |
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA3A616563C128D80E-human-1-1 |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA3A616563C128D80E-inspectai-1-1 |